Verition Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.85M Hold
446,947
– – 0.01% 1170
2026
Q2
$1.64M Buy
446,947
+34,200
+8% +$114K 0.01% 1202
2026
Q1
$1.27M Hold
412,747
– – 0.01% 1215
2025
Q4
$1.69M Buy
412,747
+358,169
+656% +$1.77M 0.01% 1760
2025
Q3
$266K Sell
54,578
-168,638
-76% -$886K ﹤0.01% 3351
2025
Q2
$1.13M Buy
223,216
+113,703
+104% +$559K 0.01% 2381
2025
Q1
$579K Buy
+109,513
New +$798K ﹤0.01% 2492
2023
Q2
– Sell
-33,400
Closed -$223K – 2492
2023
Q1
$223K Buy
+33,400
New +$265K ﹤0.01% 1705

Other funds holding RXRX

Verition Fund Management's RXRX Position: Q3 2026 in Review

Verition Fund Management held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 446,947 shares worth $1.85M. The position accounts for 0.01% of the portfolio, ranked #1170.

Verition Fund Management first reported a position in RXRX in Q1 2023 and has held it in 8 quarters since. 354 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Verition Fund Management held 446,947 shares of Recursion Pharmaceuticals worth $1.85M as of Q3 2026.
  • Verition Fund Management left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q3 2026, its #1170 holding.
  • Verition Fund Management first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
  • 354 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.